EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58 (654 d 16:32 ago) – Posting: # 20959
Views: 4,592

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,

Complete thread:

 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time: Wednesday 14:31 CEST (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz